[
  {
    "ts": "2025-11-20T04:02:47+00:00",
    "headline": "3 Reasons HOLX is Risky and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
    "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "cd664ad5-cdd9-3ad3-b93b-0bee6f83f182",
      "content": {
        "id": "cd664ad5-cdd9-3ad3-b93b-0bee6f83f182",
        "contentType": "STORY",
        "title": "3 Reasons HOLX is Risky and 1 Stock to Buy Instead",
        "description": "",
        "summary": "Over the past six months, Hologic has been a great trade, beating the S&P 500 by 20%. Its stock price has climbed to $74.17, representing a healthy 31.3% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
        "pubDate": "2025-11-20T04:02:47Z",
        "displayTime": "2025-11-20T04:02:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "HOLX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IA27MUxQWSS5U_aghxi8Pw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AP1CY6lUwaLn8kK9D5f25Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/79dab4cf82f2f6c9517c9ca1f86b9ec6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-holx-risky-1-040247006.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:31:25+00:00",
    "headline": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
    "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
    "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
      "content": {
        "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
        "contentType": "STORY",
        "title": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
        "description": "",
        "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
        "pubDate": "2025-11-20T14:31:25Z",
        "displayTime": "2025-11-20T14:31:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "TPG"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "RNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:31:25+00:00",
    "headline": "US healthcare group Abbott bets on cancer screening technology in $23bn deal",
    "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
    "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
      "content": {
        "id": "815bc36f-87b9-385e-82c0-238dc7c70cd8",
        "contentType": "STORY",
        "title": "US healthcare group Abbott bets on cancer screening technology in $23bn deal",
        "description": "",
        "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
        "pubDate": "2025-11-20T14:31:25Z",
        "displayTime": "2025-11-20T14:31:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-strikes-23bn-deal-cologuard-143125101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "TPG"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "HOLX"
            },
            {
              "symbol": "RNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]